A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)

Roche

Status: Completed

Conditions: Anemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01356589

ML25289

Details and patient eligibility

About

This retrospective observational study will assess the incidence of hemoglobin cycling in chronic kidney disease (stage 3, 4, and 5) patients with renal anemia treated with Mircera (methoxy polyethylene glycol-epoetin beta). Data will be collected from each patient from a 9-month treatment period.

Enrollment: 1,288 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Chronic kidney disease in predialysis (stage 3 and 4) and dialysis
• Renal anemia treated with Mircera according to label for at least 9 months before date of signed informed consent

Exclusion criteria

• Participation in an interventional clinical trial within the retrospective observation period
• Contraindications to Mircera administration as per label or judged by the investigator

Trial design

1,288 participants in 1 patient group

Cohort